Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies

Journal of Autoimmunity

Volumn 15, Issue 2, 2000, Pages 249-253

  Khamashta, Munther A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anticardiolipin; Lupus; Lupus anticoagulant

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS WASTAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; THROMBOSIS;

EID: 0033826263     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.2000.0421     Document Type: Conference Paper

References (22)

1. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
2. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four year prospective study from the Italian registry
3. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
4. Antiphospholipid antibodies and stroke: An epidemiotogicat perspective
5. Clinical consequences of antiphospholipid antibodies: An historic cohort study
6. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders
7. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus
8. Influence of disease duration, continued follow-up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus
9. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients
10. Risk of venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus
11. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk
12. Collaborative overview of randomised trials of antiplatelet therapy-II reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
13. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
14. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE
15. Hydroxychloroquine use in the Baltimore lupus cohort: Effects on lipids, glucose and thrombosis
16. Hydroxychloroquine reverse thrombogenic properties of antiphospholipid antibodies in mice
17. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
18. Is warfarin being underused in the treatment of elderly persons with atrial fibrillation?
19. Very low doses of warfarin can prevent thrombosis in central venous catheters: A randomized prospective trial
20. Double-blind randomised trial of Very low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
21. The antiphospholipid antibody syndrome (Hughes Syndrome): Therapeutic aspects
22. Management of thrombosis in the antiphospholipid syndrome